ETOP and its role in lung cancer research in Europe

Détails

ID Serval
serval:BIB_3CC04BA10483
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Compte-rendu: analyse d'une oeuvre publiée.
Collection
Publications
Institution
Titre
ETOP and its role in lung cancer research in Europe
Périodique
Schweizer Krebsbulletin, Nr 2/2017
Auteur⸱e⸱s
Roschitzki-Voser H, Maibach R, Stahel R, Peters S
Statut éditorial
Publié
Date de publication
01/02/2017
Langue
anglais
Résumé
Over the past 10 years, the treatment for lung cancer has drastically changed from chemotherapy - as the unique sole modality - to targeted therapies, immunotherapy and refinement of complex multimodality treatments. The de- velopment of targeted therapies and potent agents such as tyrosine kinase inhibitors shifted the therapeutic approach towards personalised medicine, where patients are treated in the context of their driver mutations
Mots-clé
Lung cancer, targeted therapy, EGFR mutation, immunotherapy
Création de la notice
08/02/2018 16:47
Dernière modification de la notice
21/11/2020 6:26
Données d'usage